Xilio Therapeutics announces 1-for-14 reverse stock split to regain Nasdaq compliance

Xilio Therapeutics, Inc.

Effective 5:00 p.m. ET on March 13, 2026; trading on split-adjusted basis starts March 16 under ticker XLO.
Outstanding shares reduce from ~73.5M to ~5.2M; authorized shares and par value unchanged.
Purpose is to increase per-share price to meet Nasdaq minimum $1.00 bid requirement.
No fractional shares issued; stockholders receiving cash in lieu of fractional shares.
Stockholders approved reverse split at Special Meeting held February 23, 2026; ratio set by Board.

item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Xilio Therapeutics, Inc. issued common stock.

Security: common stock

Exact text from the filing

will implement a 1-for-14 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Xilio Therapeutics, Inc.: Filed a Certificate of Amendment to effect a 1-for-14 reverse stock split of common stock (effective 2026-03-13).

Change: charter amendment
Effective: 2026-03-13

Exact text from the filing

On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

View on SEC.gov

Browse all equity issuances →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-103150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.